Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability
Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to eval...
Gespeichert in:
Veröffentlicht in: | Clinical & experimental neuroimmunology 2015-08, Vol.6 (3), p.275-280 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 280 |
---|---|
container_issue | 3 |
container_start_page | 275 |
container_title | Clinical & experimental neuroimmunology |
container_volume | 6 |
creator | Nakashima, Ichiro Harada, Naozumi Nakaya, Fuyuki |
description | Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability. |
doi_str_mv | 10.1111/cen3.12216 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1700594389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3766192391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</originalsourceid><addsrcrecordid>eNpNkNtKw0AQhoMoWLQ3PsGCd0LqHpJs4p2UHixFpSiCN8smO6mraRJ3N9U-ha_s1lZxbmbg_-b0B8EZwQPi47KAmg0IpSQ5CHqEx1lIsoQc_quPg761r9gHS9OIR73gawG2q5xFTYla6TTULjTQNsaBQk3nimYFSNdoJltZg4VfyKIP7V7QyvfqtgJkiwpMY7W9QqO1rDpPNfV2qHvxIqzBaLdBslaoNc3SgLV7fSm1Q0pbmevKI6fBUSkrC_19Pgkex6OH4TSc301uhtfzsKBJlIRxnKVUUc4ZlSnFSZpyjjlRMsNZlOUs5pGSkhVAQNIkVxiiPM4lTlWpCC0TdhKc7-b6c947sE68Np2p_UpBOMZxFrE089TFjir8b9ZAKVqjV9JsBMFi67nYei5-PPdwuIO1dfD5R0rzJhLOeCyebidiGi3G93g2FM_sG-aLhgI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1700594389</pqid></control><display><type>article</type><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</creator><creatorcontrib>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</creatorcontrib><description>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</description><identifier>ISSN: 1759-1961</identifier><identifier>EISSN: 1759-1961</identifier><identifier>DOI: 10.1111/cen3.12216</identifier><language>eng</language><publisher>Ube: Blackwell Publishing Ltd</publisher><subject>disease progression ; Multiple sclerosis ; Patient Determined Disease Steps ; Patients ; questionnaires</subject><ispartof>Clinical & experimental neuroimmunology, 2015-08, Vol.6 (3), p.275-280</ispartof><rights>Copyright © 2015 Japanese Society for Neuroimmunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Nakashima, Ichiro</creatorcontrib><creatorcontrib>Harada, Naozumi</creatorcontrib><creatorcontrib>Nakaya, Fuyuki</creatorcontrib><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><title>Clinical & experimental neuroimmunology</title><addtitle>Clin Exp Neuroimmunol</addtitle><description>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</description><subject>disease progression</subject><subject>Multiple sclerosis</subject><subject>Patient Determined Disease Steps</subject><subject>Patients</subject><subject>questionnaires</subject><issn>1759-1961</issn><issn>1759-1961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpNkNtKw0AQhoMoWLQ3PsGCd0LqHpJs4p2UHixFpSiCN8smO6mraRJ3N9U-ha_s1lZxbmbg_-b0B8EZwQPi47KAmg0IpSQ5CHqEx1lIsoQc_quPg761r9gHS9OIR73gawG2q5xFTYla6TTULjTQNsaBQk3nimYFSNdoJltZg4VfyKIP7V7QyvfqtgJkiwpMY7W9QqO1rDpPNfV2qHvxIqzBaLdBslaoNc3SgLV7fSm1Q0pbmevKI6fBUSkrC_19Pgkex6OH4TSc301uhtfzsKBJlIRxnKVUUc4ZlSnFSZpyjjlRMsNZlOUs5pGSkhVAQNIkVxiiPM4lTlWpCC0TdhKc7-b6c947sE68Np2p_UpBOMZxFrE089TFjir8b9ZAKVqjV9JsBMFi67nYei5-PPdwuIO1dfD5R0rzJhLOeCyebidiGi3G93g2FM_sG-aLhgI</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Nakashima, Ichiro</creator><creator>Harada, Naozumi</creator><creator>Nakaya, Fuyuki</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20150801</creationdate><title>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</title><author>Nakashima, Ichiro ; Harada, Naozumi ; Nakaya, Fuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2646-55982d27732a82068877071da90949b3574daa3ce1ea26bd0e4b5ba08dfd12f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>disease progression</topic><topic>Multiple sclerosis</topic><topic>Patient Determined Disease Steps</topic><topic>Patients</topic><topic>questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakashima, Ichiro</creatorcontrib><creatorcontrib>Harada, Naozumi</creatorcontrib><creatorcontrib>Nakaya, Fuyuki</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Clinical & experimental neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakashima, Ichiro</au><au>Harada, Naozumi</au><au>Nakaya, Fuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability</atitle><jtitle>Clinical & experimental neuroimmunology</jtitle><addtitle>Clin Exp Neuroimmunol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>6</volume><issue>3</issue><spage>275</spage><epage>280</epage><pages>275-280</pages><issn>1759-1961</issn><eissn>1759-1961</eissn><abstract>Objective To evaluate the degree of severity and disability progression in Japanese patients with multiple sclerosis (MS) using descriptive study methods. Methods Postal questionnaires were sent to patients through three Japanese MS patients' associations. Survey participants were asked to evaluate their disability and MS severity based on two scales: the Patient Determined Disease Steps (PDDS) and the Short Form-8 Health Survey. Results A total of 789 MS patients were surveyed. Approximately 45% of patients had gait disability (PDDS score of 3) or higher. Patients with a higher age of MS onset had rapid progression of disease. The mean duration from first symptom of MS to treatment initiation was 4.5 years. The time to treatment initiation was longer for the younger onset group, ≤29 years-of-age, than that of the older onset group, ≥40 years-of-age (6.2 years vs 2.2 years, respectively). The PDDS showed two-stage disability progression: while progression time to a PDDS score of 2 varied, progression time from a PDDS score of 2 to a score of 4 was similar across the participants. Conclusions Based on the patient-reported disability progression of MS, we showed that the possibility of severity and MS disease progression between Japanese and Western countries might be similar. The PDDS could be a useful alternative to assess MS disability.</abstract><cop>Ube</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/cen3.12216</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1759-1961 |
ispartof | Clinical & experimental neuroimmunology, 2015-08, Vol.6 (3), p.275-280 |
issn | 1759-1961 1759-1961 |
language | eng |
recordid | cdi_proquest_journals_1700594389 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | disease progression Multiple sclerosis Patient Determined Disease Steps Patients questionnaires |
title | Results of patient-reported outcome in Japanese patients with multiple sclerosis: Evaluation of the severity and progression of gait disability |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A02%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20patient-reported%20outcome%20in%20Japanese%20patients%20with%20multiple%20sclerosis:%20Evaluation%20of%20the%20severity%20and%20progression%20of%20gait%20disability&rft.jtitle=Clinical%20&%20experimental%20neuroimmunology&rft.au=Nakashima,%20Ichiro&rft.date=2015-08-01&rft.volume=6&rft.issue=3&rft.spage=275&rft.epage=280&rft.pages=275-280&rft.issn=1759-1961&rft.eissn=1759-1961&rft_id=info:doi/10.1111/cen3.12216&rft_dat=%3Cproquest_cross%3E3766192391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1700594389&rft_id=info:pmid/&rfr_iscdi=true |